LEADER 05330nam  22006133u 450 
001 9910459728203321
005 20210112195303.0
010   $a92-4-069352-1
035   $a(CKB)3710000000326509
035   $a(EBL)1910127
035   $a(OCoLC)899158487
035   $a(SSID)ssj0001668410
035   $a(PQKBManifestationID)16461035
035   $a(PQKBTitleCode)TC0001668410
035   $a(PQKBWorkID)15003758
035   $a(PQKB)10712870
035   $a(MiAaPQ)EBC1910127
035   $a(Au-PeEL)EBL1910127
035   $a(EXLCZ)993710000000326509
100   $a20151005d2015||||  u||            |
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aGuidelines on the Management of Latent Tuberculosis Infection$b[electronic resource]
210   $cWorld Health Organization$d2015
215   $a1 online resource (38 p.)
300   $aDescription based upon print version of record.
311   $a92-4-154890-8 
327   $a""Cover""; ""Cover""; ""Contents""; ""Contents""; ""Acknowledgements""; ""Acknowledgements""; ""Abbreviations""; ""Abbreviations""; ""Declaration and management of conflict of interest""; ""Declaration and management of conflict of interest""; ""Executive summary""; ""Executive summary""; ""1. Background and process""; ""1. Background and process""; ""1.1. Background""; ""1.1. Background""; ""1.2. Scope of the guidelines""; ""1.2. Scope of the guidelines""; ""1.3. Target audience""; ""1.3. Target audience""; ""1.4. Development of the guidelines""; ""1.4. Development of the guidelines""
327   $a""1.5. Quality of evidence and strength of the recommendations""""1.5. Quality of evidence and strength of the recommendations""; ""2. Recommendations""; ""2. Recommendations""; ""2.1. Identification of at-risk populations for LTBI testing and treatment""; ""2.1. Identification of at-risk populations for LTBI testing and treatment""; ""2.1.1. Summary of the evidence""; ""2.1.1. Summary of the evidence""; ""2.1.2. Balance of benefits and harms""; ""2.1.2. Balance of benefits and harms""; ""2.1.3. Values and preferences of clients and health-care providers""
327   $a""2.1.3. Values and preferences of clients and health-care providers""""2.1.4. Resource considerations""; ""2.1.4. Resource considerations""; ""2.2. Algorithm to test and treat LTBI""; ""2.2. Algorithm to test and treat LTBI""; ""2.2.1. Summary of the evidence""; ""2.2.1. Summary of the evidence""; ""2.2.2. Balance of benefits and harms""; ""2.2.2. Balance of benefits and harms""; ""2.2.3. Values and preferences of clients and health-care providers""; ""2.2.3. Values and preferences of clients and health-care providers""; ""2.2.4. Resource considerations""; ""2.2.4. Resource considerations""
327   $a""2.3. Treatment options for LTBI""""2.3. Treatment options for LTBI""; ""2.3.1. Summary of the evidence""; ""2.3.1. Summary of the evidence""; ""2.3.2. Balance of benefits and harms""; ""2.3.2. Balance of benefits and harms""; ""2.3.3. Values and preferences of clients and health-care providers""; ""2.3.3. Values and preferences of clients and health-care providers""; ""2.3.4. Resource considerations""; ""2.3.4. Resource considerations""; ""2.4. Preventive treatment for contacts of MDR-TB cases""; ""2.4. Preventive treatment for contacts of MDR-TB cases""; ""2.4.1. Summary of the evidence""
327   $a""2.4.1. Summary of the evidence""""2.4.2 Balance of benefits and harms""; ""2.4.2 Balance of benefits and harms""; ""2.4.3. Values and preferences of clients and health-care providers""; ""2.4.3. Values and preferences of clients and health-care providers""; ""2.4.4. Resource considerations""; ""2.4.4. Resource considerations""; ""2.4.5. Conclusions""; ""2.4.5. Conclusions""; ""3. Issues in Implementation""; ""3. Issues in Implementation""; ""3.1. Adverse events monitoring""; ""3.1. Adverse events monitoring""; ""3.2. Risk of drug resistance following LTBI treatment""
327   $a""3.2. Risk of drug resistance following LTBI treatment""
330   $aLatent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast majority of infected persons have no signs or symptoms of TB but are at risk for developing activetuberculosis (TB) disease. This can be averted by preventive treatment. These Guidelines on the management of latent tuberculosis infection were developed in accordanceto the requirements and recommended p
606   $aTuberculosis -- Patients -- Treatment
606   $aTuberculosis -- Prevention
606   $aTuberculosis -- Treatment
608   $aElectronic books.
615  4$aTuberculosis -- Patients -- Treatment.
615  4$aTuberculosis -- Prevention.
615  4$aTuberculosis -- Treatment.
676   $a616.109236
712 02$aWorld Health Organization.
712 02$aWorld Health Organization.
801  0$bAU-PeEL
801  1$bAU-PeEL
801  2$bAU-PeEL
906   $aBOOK
912   $a9910459728203321
996   $aGuidelines on the Management of Latent Tuberculosis Infection$92452308
997   $aUNINA